Norelgestromin/ethinylestradiol
![]() Ortho Evra brand of birth control patch | |
Combination of | |
---|---|
Norelgestromin | Progestogen |
Ethinylestradiol | Estrogen |
Names | |
Trade names | Ortho Evra, Xulane, Evra, others[1] |
| |
Clinical data | |
Main uses | Pregnancy prevention[2] |
Side effects | Headache, nausea, breast tenderness, irregular uterine bleeding, blood clots[2][3] |
Pregnancy category |
|
Routes of use | Transdermal (patch) |
External links | |
AHFS/Drugs.com | Professional Drug Facts |
MedlinePlus | a602006 |
Legal | |
License data | |
Legal status | |
Chemical and physical data | |
Formula | C41H53NO4 |
Molar mass | 623.878 g·mol−1 |
3D model (JSmol) | |
| |
|
Norelgestromin/ethinylestradiol, sold under the brand name Evra among others, is a type of birth control patch used to prevent pregnancy.[2] Other benefits include the ability to determine when periods occur, improved acne, and less PMS.[6] It is generally applied to the skin for a week at a time for three weeks, followed by a fourth week patch-free.[2] If the patch-free interval is longer than seven days, additional birth control, such as condoms, should be used.[2] Patches should be applied the same day of the week to altering areas of the buttock, abdomen, upper arm, or upper back.[2]
Common side effects include headache, nausea, breast tenderness, and irregular uterine bleeding.[2][3] Use is not recommended in those with liver problems, migraines with aura, or at risk of blood clots.[2] Those at risk of blood clots include those over 35 years old who smoke.[3] It works less well in those weighing more than 90 kilograms (200 lb) or with a BMI ≥ 30 kg/m2.[2][3] It contains the progestin, norelgestromin and the estrogen, ethinylestradiol.[3][2]
The combination was approved for medical use in the United States in 2001 and Europe in 2002.[7][8][2] A generic version became available in 2014.[6] They are used by about 0.4% of women not wanting to become pregnant in the United States.[9] In the United States it costs about 35 USD per month as of 2024.[10] As of 2016, the brand Ortho Evra has been discontinued in the United States while other brands continues to be marketed.[11][3]
Medical uses
In the United States norelgestromin/ethinylestradiol is indicated for the prevention of pregnancy in women with a BMI < 30 kg/m2 for whom a transdermal delivery system is an appropriate method of contraception.[3]
In the European Union, norelgestromin/ethinylestradiol is indicated for use as female contraception.[2]
Society and culture
Cost
The cost in the U.S. of this medication is about $46 (USD) for 1 month of transdermal extended release film 35 mcg-150 mcg/24 hr[12]
-
Norelgestromin/ethinylestradiol costs (US)
-
Norelgestromin/ethinylestradiol prescriptions (US)
See also
- Combined injectable contraceptive
- Contraceptive vaginal ring
- Oral contraceptive formulations
- List of combined sex-hormonal preparations
References
- ↑ "DailyMed - Search Results for Norelgestromin_and_ethinyl_estradiol". dailymed.nlm.nih.gov. Archived from the original on 1 January 2022. Retrieved 19 February 2024.
- ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 "Evra EPAR". European Medicines Agency (EMA). Archived from the original on 12 November 2020. Retrieved 4 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 "Xulane- norelgestromin and ethinyl estradiol patch". DailyMed. 7 April 2020. Archived from the original on 6 July 2020. Retrieved 4 July 2020.
- ↑ "Evra Product information". Health Canada. 2018-06-21. Archived from the original on 18 February 2020. Retrieved 17 February 2020.
- ↑ "Evra transdermal patch - Summary of Product Characteristics (SmPC)". (emc). 26 June 2020. Archived from the original on 24 October 2020. Retrieved 4 July 2020.
- ↑ 6.0 6.1 Cason, Patty; Cwiak, Carrie; Kowal, Deborah; Edelman, Alison (26 September 2023). "12". Contraceptive Technology (22 ed.). Jones & Bartlett Learning. pp. 359–405. ISBN 978-1-284-25503-4. Retrieved 18 February 2024.
- ↑ "Ortho Evra (norelgestromin/ethinyl estradiol transdermal system) Initial U.S. Approval: 2001". DailyMed. 12 July 2018. Archived from the original on 5 July 2020. Retrieved 4 July 2020.
- ↑ "Drug Approval Package: Ortho EVRA (Norelgestromin/Ethinyl Estradiol Transdermal System NDA #21-180". U.S. Food and Drug Administration (FDA). Archived from the original on 5 July 2020. Retrieved 4 July 2020.
- ↑ Cason, Patty; Cwiak, Carrie; Kowal, Deborah; Edelman, Alison (26 September 2023). "5". Contraceptive Technology. Jones & Bartlett Learning. pp. 125–163. ISBN 978-1-284-25503-4. Retrieved 18 February 2024.
- ↑ "Xulanegeneric Ortho Evra". GoodRx. Archived from the original on 9 May 2023. Retrieved 18 February 2024.
- ↑ "Ortho Evra: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 5 July 2020. Retrieved 4 July 2020.
- ↑ "Ortho Evra Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 7 September 2015. Retrieved 30 March 2021.
External links
Identifiers: |
|
---|
- "Ethinyl Estradiol mixture with norelgestromin". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 9 February 2021. Retrieved 19 January 2021.
- Pages using duplicate arguments in template calls
- Drugs with non-standard legal status
- Chemical articles with unknown parameter in Infobox drug
- Infobox drug articles with contradicting parameter input
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs missing an ATC code
- Drug has EMA link
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Chemicals that do not have a ChemSpider ID assigned
- Combined hormonal contraceptives
- Transdermal patches
- RTT
- WHRTT
- All stub articles
- Genito-urinary system drug stubs